Role of Early Application Unknown; But Potentially Big
That is, presently, a big unknown. Will earlier, pre-symptomatic administration of Anavex 2-73 yield enhanced therapeutic (or prophylactic) outcomes?
Personally, I expect such a finding; that those taking the Anavex drug at earlier ages, before any gross or frank disease symptoms present, will have greatly enhanced benefits. There are several reasons this could occur, including the following.
Again, the Anavex sigma-1 receptor agonists work, restore normalized neuron function, by re-connecting disjointed neuron organelles, mitochondria with their associated endoplasmic reticula. When those two cellular structures are in proper alignment, operating mutually, the neuron functions normally.
But when things fall apart, become disconnected, reaction-controlling enzymes cannot be properly made. A disease condition arises. Things operate badly within the neuron.
A parallel could be drawn with a car engine. Off the assembly line, all of the many parts of the engine are working well. But what happens if, say, the oil pump forcing pressurized oil into bearings and surfaces begins to fail. The engine, of course, then fails. When would you want a malfunctioning oil pump fixed, “treated?” Before it actually fails, or after declining oil pressure symptoms appear?
Repair after the engine has been damaged by poor lubrication will be expensive, if even possible. Fixing the oil pump before it fails saves the engine.
Will the same scenario be discovered in the now-started clinical trial in Australia? Will it be discovered that of the 300 taking Anavex 2-73 against their well-diagnosed Alzheimer’s, better outcomes will occur in those with less-developed symptoms, those treated at ever earlier stages of the disease?
Makes complete sense. Much less to “fix” at early disease stages, before irreparable damage has been done.
Then, finally, will it be discovered that preliminary administration of Anavex 2-73, even before any symptoms appear, simply prevents the occurrence of Alzheimer’s and/or other central nervous system diseases?
If I had genomic indications of any genetic vulnerabilities to Alzheimer’s, I know when I’d want to be popping an Anavex pill each day — as soon as I learned of this untoward genomic analysis.
When Anavex 2-73 gains approval for use (in any country, perhaps or probably first in Australia), what factors will prescribing physicians consider in deciding when to first dose patients with the drug? “Mrs. Dorgelmeyer, it does appear that your husband is having a few memory problems. But we don’t want to get him on this new Alzheimer’s drug too early. We can’t be sure that would be good. Have him check back in a year.”
That’s when medical practice tort lawyers and medical practice insurance parties will enter the scene, of course.
If efficacy of any sort is discovered in the trial (it will be), it’s going to be interesting to see how, and how long all of this plays out; both for patients themselves, and for those (of us) with financial stakes in Anavex Life Sciences Corp.
AI
